

Application No. 10/532,690
Amendment dated August 4, 2009
Page 2

Amendments to the Claims:

Please amend claim 2 without prejudice, as shown in the listing of claims that follows. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (canceled).

2. (Currently amended) A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, Type II Diabetes, Type I Diabetes, ~~diabetes~~, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of the biologically active agent effective to treat the condition;

wherein the agent is selected from the group consisting of:

4-(4-benzyloxy-3-chlorophenyl)-4-oxobutanoic acid;
Methyl 4-(4-benzyloxy-2-methoxyphenyl)-4-oxobutanoate;
Ethyl 4-(4-cyclohexylmethoxyphenyl)-4-oxobutanoate;
4-(3-chloro-4-cyclopropylmethoxyphenyl)-4-oxobutanoic acid;
Ethyl 3-(4-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxyphenyl)-3-oxopropanoate;
Ethyl 3-(2-benzyloxyphenyl)-3-oxopropanoate;
Methyl 3-(3-(2,6-dichlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-(4-chlorobenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(3-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;

Ethyl 3-(2-(4-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(2-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(2-(3-methoxybenzyloxy)phenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-chlorophenyl)-3-oxopropanoate;
Ethyl 3-(4-benzyloxy-3-methoxyphenyl)-3-oxopropanoate;
Ethyl 3-(3-benzyloxy-4-methoxyphenyl)-3-oxopropanoate;
and pharmaceutically acceptable salts thereof.

3. (Original) The method of claim 2, wherein the agent is administered orally.
4. (Original) The method of claim 2, wherein the subject is a human.
5. (Original) The method of claim 4, wherein the agent is administered in an amount from one milligram to four hundred milligrams per day.
6. (Original) The method of claim 2, wherein the condition is insulin resistance syndrome or Type II Diabetes.
7. (Original) The method of claim 2, wherein the condition is Type 1 Diabetes.
8. (Previously presented) The method of claim 2, wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of atherosclerosis associated with diabetes, obesity associated with diabetes, hypertension associated with diabetes, hyperlipidemia associated with diabetes, fatty liver disease associated with diabetes, nephropathy associated with diabetes,

neuropathy associated with diabetes, retinopathy associated with diabetes, foot ulceration associated with diabetes and cataracts associated with diabetes.

9. (Canceled)

10. (Canceled)